Metoklopramidklorid Hameln

Metoclopramide Hydrochloride Monohydrate, the active ingredient in Metoklopramidklorid Hameln, is a dopamine D2 receptor antagonist presented as a sterile injectable solution for intramuscular and intravenous use. It treats nausea, vomiting and gastroparesis in adult patients.

GNH USA supplies Metoklopramidklorid Hameln as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metoclopramide is used to manage conditions related to nausea, vomiting and delayed gastric emptying.

- Nausea and vomiting: reduces episodes in various clinical settings. - Post‑operative nausea and vomiting: prevents and treats nausea after surgery. - Gastroparesis: enhances gastric motility and relieves related symptoms. - Chemotherapy‑induced nausea: helps control nausea associated with anticancer treatment.

Metoclopramide may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Drowsiness: feeling unusually sleepy or fatigued. - Restlessness: mild agitation or inner tension. - Diarrhea: loose or frequent stools. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Extrapyramidal symptoms: involuntary muscle movements or dystonia. - Neuroleptic malignant syndrome: rare, life‑threatening reaction with fever and rigidity. - Tardive dyskinesia: persistent involuntary facial movements. - Severe hypotension: marked drop in blood pressure.

Before using Metoklopramide, consider the following safety measures.

- Renal or hepatic impairment: assess function and adjust use accordingly. - Extrapyramidal monitoring: watch for signs of muscle rigidity or tremor. - Parkinson's disease: avoid or use with caution due to dopamine blockade. - Known hypersensitivity: discontinue if allergic reaction occurs. - Elderly patients: start with lower doses and monitor closely. - Store at ambient temperature: keep in original packaging, protect from moisture.

Metoclopramide can interact with several medicines; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Antipsychotics (e.g., haloperidol): may increase risk of extrapyramidal symptoms. - MAO inhibitors: can potentiate central nervous system effects. - CNS depressants (e.g., opioids, benzodiazepines): may enhance sedation. - CYP2D6 inhibitors: may raise metoclopramide plasma levels.

Moderate Interactions (Monitor Closely): - Anticholinergics: may reduce pro‑kinetic effect. - SSRIs and tricyclic antidepressants: monitor for additive serotonergic activity. - Diabetic agents: watch for masked hypoglycemia symptoms.